Literature DB >> 1309230

Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission.

M C Garrett1, P Soares-da-Silva.   

Abstract

Levels of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), noradrenaline (NA), 3-methoxy-4-hydroxyphenylglycol (MHPG), and 5-hydroxyindoleacetic acid (5-HIAA) in the CSF of patients with Huntington's disease (HD) were measured by HPLC. CSF DA, DOPAC, and MHPG levels were found to be increased in HD patients. Levels of HVA, 5-HIAA, and NA in the CSF of HD patients did not differ from those of controls. Changes in CSF DA and DOPAC levels were consistent with previous findings of increased DA tissue content in some brain areas of patients with HD. These results suggest that CSF DOPAC levels could be a more reliable index of overactive dopaminergic brain systems in HD than CSF HVA levels.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1309230     DOI： 10.1111/j.1471-4159.1992.tb09283.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN： 0022-3042            Impact factor:   5.372


  22 in total

Review 1.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 2.  Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

Authors:  L A Raymond; V M André; C Cepeda; C M Gladding; A J Milnerwood; M S Levine
Journal:  Neuroscience       Date:  2011-08-27       Impact factor: 3.590

Review 3.  Mitochondrial Abnormalities and Synaptic Damage in Huntington's Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics.

Authors:  Neha Sawant; Hallie Morton; Sudhir Kshirsagar; Arubala P Reddy; P Hemachandra Reddy
Journal:  Mol Neurobiol       Date:  2021-09-14       Impact factor: 5.590

Review 4.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

5.  Serum iron, total iron binding capacity and ferritin in early Huntington disease patients.

Authors:  P J Morrison; N C Nevin
Journal:  Ir J Med Sci       Date:  1994-05       Impact factor: 1.568

Review 6.  Disrupted striatal neuron inputs and outputs in Huntington's disease.

Authors:  Anton Reiner; Yun-Ping Deng
Journal:  CNS Neurosci Ther       Date:  2018-04       Impact factor: 5.243

7.  Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice.

Authors:  Tristano Pancani; Daniel J Foster; Mark S Moehle; Terry Jo Bichell; Emma Bradley; Thomas M Bridges; Rebecca Klar; Mike Poslusney; Jerri M Rook; J Scott Daniels; Colleen M Niswender; Carrie K Jones; Michael R Wood; Aaron B Bowman; Craig W Lindsley; Zixiu Xiang; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-27       Impact factor: 11.205

8.  Platelet-derived extracellular vesicles in Huntington's disease.

Authors:  Hélèna L Denis; Jérôme Lamontagne-Proulx; Isabelle St-Amour; Sarah L Mason; Andreas Weiss; Sylvain Chouinard; Roger A Barker; Eric Boilard; Francesca Cicchetti
Journal:  J Neurol       Date:  2018-09-12       Impact factor: 4.849

9.  Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine.

Authors:  P Calabresi; P Gubellini; B Picconi; D Centonze; A Pisani; P Bonsi; P Greengard; R A Hipskind; E Borrelli; G Bernardi
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

10.  Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice.

Authors:  Yunping Deng; Hongbing Wang; Marion Joni; Radhika Sekhri; Anton Reiner
Journal:  J Comp Neurol       Date:  2020-09-20       Impact factor: 3.215
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.